These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35006946)

  • 1. Immunogenicity and Vaccine Efficacy Boosted by Engineering Human Heavy Chain Ferritin and Chimeric Hepatitis B Virus Core Nanoparticles.
    Qu Y; Zhang B; Wang Y; Yin S; Sun Y; Middelberg A; Bi J
    ACS Appl Bio Mater; 2021 Sep; 4(9):7147-7156. PubMed ID: 35006946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity study of engineered ferritins with C- and N-terminus insertion of Epstein-Barr nuclear antigen 1 epitope.
    Qu Y; Zhang B; Wang Y; Yin S; Pederick JL; Bruning JB; Sun Y; Middelberg A; Bi J
    Vaccine; 2021 Aug; 39(34):4830-4841. PubMed ID: 34284876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice.
    Sazegari S; Akbarzadeh Niaki M; Afsharifar A; Niazi A; Derakhshandeh A; Moradi Vahdat M; Hemmati F; Eskandari MH
    Microb Cell Fact; 2023 Feb; 22(1):39. PubMed ID: 36841778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety.
    Schödel F; Peterson D; Milich D
    Intervirology; 1996; 39(1-2):104-10. PubMed ID: 8957676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity.
    Schödel F; Moriarty AM; Peterson DL; Zheng JA; Hughes JL; Will H; Leturcq DJ; McGee JS; Milich DR
    J Virol; 1992 Jan; 66(1):106-14. PubMed ID: 1370083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes.
    Sominskaya I; Skrastina D; Dislers A; Vasiljev D; Mihailova M; Ose V; Dreilina D; Pumpens P
    Clin Vaccine Immunol; 2010 Jun; 17(6):1027-33. PubMed ID: 20410327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.
    Skrastina D; Petrovskis I; Lieknina I; Bogans J; Renhofa R; Ose V; Dishlers A; Dekhtyar Y; Pumpens P
    PLoS One; 2014; 9(12):e114006. PubMed ID: 25436773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis.
    Yin Y; Zhang J; Dong D; Liu S; Guo Q; Song X; Li G; Fu L; Xu J; Chen W
    Vaccine; 2008 Oct; 26(46):5814-21. PubMed ID: 18786589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes.
    Schödel F; Peterson D; Hughes J; Wirtz R; Milich D
    J Biotechnol; 1996 Jan; 44(1-3):91-6. PubMed ID: 8717391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion modification enhances anthrax specific immunity and protective efficacy of a hepatitis B core particle-based anthrax epitope vaccine.
    Yin Y; Zhang S; Cai C; Zhang J; Dong D; Guo Q; Fu L; Xu J; Chen W
    Immunobiology; 2014 Feb; 219(2):97-103. PubMed ID: 24054942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit.
    Broos K; Janssens ME; De Goeyse I; Vanlandschoot P; Leroux-Roels G; Geysen D; Guisez Y
    Clin Vaccine Immunol; 2008 May; 15(5):852-8. PubMed ID: 18367580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus core particles displaying Mycobacterium tuberculosis antigen ESAT-6 enhance ESAT-6-specific immune responses.
    Yin Y; Li H; Wu S; Dong D; Zhang J; Fu L; Xu J; Chen W
    Vaccine; 2011 Aug; 29(34):5645-51. PubMed ID: 21689705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo.
    Zhang Y; Song S; Liu C; Wang Y; Xian X; He Y; Wang J; Liu F; Sun S
    Cell Immunol; 2007 May; 247(1):18-27. PubMed ID: 17707782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preparation and characterization of HBc virus like particles with site-directed coupling function].
    Liu D; Li B; Bi C; Qiao H; Wu X
    Sheng Wu Gong Cheng Xue Bao; 2020 Jul; 36(7):1440-1449. PubMed ID: 32748602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles.
    Dhanasooraj D; Kumar RA; Mundayoor S
    Int J Nanomedicine; 2013; 8():835-43. PubMed ID: 23486691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coimmunization with IL-15 plasmid enhances the longevity of CD8 T cells induced by DNA encoding hepatitis B virus core antigen.
    Zhang W; Dong SF; Sun SH; Wang Y; Li GD; Qu D
    World J Gastroenterol; 2006 Aug; 12(29):4727-35. PubMed ID: 16937447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Hepatitis B Virus Core Variants that Expose Foreign C-Terminal Insertions on the Outer Surface of Virus-Like Particles.
    Dishlers A; Skrastina D; Renhofa R; Petrovskis I; Ose V; Lieknina I; Jansons J; Pumpens P; Sominskaya I
    Mol Biotechnol; 2015 Dec; 57(11-12):1038-49. PubMed ID: 26446016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses.
    Zheng D; Chen S; Qu D; Chen J; Wang F; Zhang R; Chen Z
    Vaccine; 2016 Dec; 34(51):6464-6471. PubMed ID: 27866773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The position of Spy Tag/Catcher system in hepatitis B core protein particles affects the immunogenicity and stability of the synthetic vaccine.
    Sheng Y; Li Z; Lin X; Ma Y; Ren Y; Su Z; Ma G; Zhang S
    Vaccine; 2023 Jul; 41(33):4867-4878. PubMed ID: 37391312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection.
    Chen X; Li M; Le X; Ma W; Zhou B
    Vaccine; 2004 Jan; 22(3-4):439-46. PubMed ID: 14670326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.